Release Date: November 21, 2022
Expiration Date:
May 31, 2023
Time to Complete Activity: 30 minutes


Presenting Faculty and Steering Committee

Rishi P. Singh, MD, FASRS
Staff Surgeon and President
Cleveland Clinic Martin Hospitals
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine
Stuart, FL

David M. Brown, MD, FACS
Clinical Professor associated with Ophthalmology
Baylor University of Medication
Director, Greater Houston Retina Research Center
Retina Consultants of Houston
Houston, TX

Carl D. Regillo, MD, FACS
Movie director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, PA


Target Audience

This activity has been designed to address the educational needs of retina specialists, retina fellows, and select comprehensive ophthalmologists.


Provider Statement

This activity is provided by Paradigm Medical Communications, LLC.     Paradigm Medical Communications  


Supporter Acknowledgment

This activity is supported by an independent medical academic grant from Regeneron
Pharmaceuticals, Inc.


Program Overview

Diabetic retinopathy/diabetic macular edema (DR/DME) continue to affect patients with diabetes at alarming rates; in fact, those with diabetes are 25 times more likely to experience blindness than those without diabetes. Adhering to current guidelines for treatment that do not reflect the availability of present medications, along with suboptimal patient responses, can be challenging when formulating an optimal treatment plan. New data regarding the use associated with anti-vascular endothelial growth factor (VEGF) prophylaxis suggest the need with regard to an evidence-based shift in order to proactive DR treatment (rather than “watch and wait”). Join Drs Brown, Regillo, and Singh for an engaging discussion on when to initiate therapy, current clinical trial data on anti-VEGF agents, and a real-world patient case presentation.


Learning Objectives

Upon completion of this exercise, participants should be able to:

  • Assess the effects of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy on diabetic retinopathy (DR)/diabetic macular edema (DME), as evidenced by recent data
  • Differentiate among new plus emerging strategies for more durable dosing associated with anti-VEGF to treat DR/DME
  • Develop therapy plans regarding patients along with DR/DME that are safe, effective, and tailored to patients’ clinical needs and personal preferences


Accreditation

Physician Certification Statement
ACCME logo Paradigm Medical Communications, LLC is accredited by the Accreditation Council intended for Continuing Healthcare Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

Physician Credit score Designation Declaration
Paradigm Medical Marketing communications, LLC designates this enduring activity to get a maximum of 0. 50 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Hardware/Software Requirements

This certified CME exercise is designed using HTML5 web components. As you navigate the video using the supplied controls, the particular slides will sync to the speaker.

Supported  Browsers (Desktop/Mobile)

Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This particular activity may contain PDF FILE documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support: If you have any technical problems or playback issues, email us at [email protected] possuindo .


Instructions pertaining to Participation

To receive a certificate associated with participation, participants must:

  • Follow instructions to register or log in with your professional information and complete the preassessment
  • View the online activity in its entirety
  • Complete and submit the online postassessment plus evaluation. You must answer 70% of the postassessment questions correctly in order to earn credit score. You will have unlimited opportunities to successfully complete the particular postassessment

A certificate of participation will be available for download/printing immediately following your successful completing the postassessment and evaluation.

For questions regarding CME credit, contact the particular Paradigm CME Department in [email protected] apresentando .

There are no fees meant for participating in this action.


Disclosure of Relevant Financial Relationships

In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education , Paradigm requires that all planners, faculty, plus others who are in the position to control the particular content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to Paradigm policy prior in order to individuals assuming their roles, and are disclosed prior to learners’ engagement inside the activity. Paradigm will be committed to providing learners with high-quality accredited ongoing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The content of this activity was independently reviewed to ensure that it is usually fair plus balanced, scientifically rigorous, evidence based, and aligned along with the public interest. All relevant relationships have already been mitigated.

David M. Brown, MD, FACS
Consultant: Adverum Biotechnologies Inc; agtc; Alexion Pharmaceuticals, Inc; Annexon, Inc; Apellis Pharmaceuticals, Incorporation; Bayer Corporation; Beyeonics Surgical; Biogen; Boehringer Ingelheim International; Celltrion Inc; Chengdu Kanghong Pharmaceutical Group Co, LTD; Clearside Biomedical; Coherus BioSciences; Gemini Therapeutics; Glaukos Company; Horizon Therapeutics plc; IVERIC bio, Incorporation; Kodiak Sciences Inc; Laboratories Théa; Lineage Cell Therapeutics, Inc; Novartis AG; Optos; Platform Health; PPD Inc; Regeneron Pharmaceutical drugs Inc; RetinAl Medical AG; Ray Therapeutics; Samsung Bioepis; Senju Pharmaceutical Co; Stealth BioTherapeutics Incorporation; Verseon International Corporation; ZHUHAI SMILEBIOTEK CO LTD
Study Funding: Adverum Biotechnologies Inc; Alderya Thereapeutics, Inc; Alexion Pharmaceuticals, Incorporation; Alimera Sciences; Alkahest, Inc.; Amgen Incorporation; Annexon, Inc; Apellis Drugs, Inc; Aura Pharmaceuticals Pvt Ltd; Bayer Corporation; Boston Image Reading Center; Boehringer Ingelheim World GmbH; Clearside Biomedical; Cleveland Clinic Foundation; EyePoint Pharmaceuticals, Inc; Gemini Therapeutics; Genentech, Inc; Graybug Vision Incorporation; Gyroscope Therapeutics Limited; Ionis Pharmaceuticals, Inc; Irenix Medical, Inc; IVERIC bio, Incorporation; Johns Hopkins; Kodiak Sciences Inc; Lowery Medical Analysis Group; LumiThera, Inc; Nanoscope Therapeutics, Inc; NEI/NH National Eye Institute/ National Wellness Institute; Neurotech Pharmacuticals, Incorporation; NGM Biopharmaceuticals, Inc; Novartis AG; Ocular Therapeutix, Inc; Ocuphire Pharma, Inc; OIRRC: Ocular Imaging Research plus Reading Center; ONS: Outlook Therapeutics; Opthea; Opthotech Corp; OPTOS; Oxurion NV; Oyster Point Pharma, Inc.; Regeneron Pharmaceuticals Incorporation; REGENXBIO Inc; Roche; SamChunDang Pharm Co, Ltd; Samsung Bioepsis; Sandoz International GmbH; Santen Pharmaceutic Co., Ltd.; Senju Pharmaceutical Co; On stealth BioTherapeutics Incorporation; UNITY Biotechnology; Xbrane Biopharma; Zeiss Essential

Carl D. Regillo, MD, FACS
Consultant: 4D Molecular Therapeutics; Adverum Biotechnologies, Inc; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Clearside Biomedical; EyePoint Pharmaceutical drugs, Inc; Genentech, Inc.; Graybug Vision Incorporation; IVERIC bio, Inc; Kodiac Sciences Inc; Lineage Cell Therapeutics, Incorporation; NGM Biopharmaceuticals; Novartis AG; Ocugen, Inc; Stealth BioTherapeutics Inc
Research Funding: Adverum Biotechnologies, Incorporation; Allergan, Inc.; Annexon Incorporation; Clearside Biomedical; EyePoint Drugs, Inc; Genentech, Inc.; IVERIC bio, Inc; Kodiac Sciences Inc; NGM Biopharmaceuticals; Regeneron Pharmaceuticals Incorporation; REGENXBIO Inc
Stocks : IVERIC bio, Incorporation; Ocugen, Inc

Rishi P. Singh, MD, FASRS
Specialist : Alcon; AsclepiX Therapeutics; Bausch Health Companies Incorporation.; Genentech, Inc.; Gyroscope Therapeutics Limited; Novartis AG; Regeneron Pharmaceuticals Incorporation

Paradigm Healthcare Communications, LLC staff members have no related financial associations with ineligible companies to disclose.

Independent peer reviewer has no relevant monetary relationships with ineligible businesses to reveal.


Disclosure of Unlabeled Use

This educational exercise may contain discussion associated with published and/or investigational uses of agents which are not really approved by the particular FDA.


Disclaimer

This particular CME action represents the views and opinions of the individual faculty, plus does not constitute the particular opinion or even endorsement associated with, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts possess been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this info, particularly as it might relate to patient diagnostic or even treatment decisions including, without having limitation, FDA-approved uses and any off-label uses.

In case included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which a good individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Marketing communications, LLC must ensure that will its activities include a balanced view of therapeutic options. Make use of generic names contributes to this impartiality. The make use of trade names should not be viewed because an endorsement of specific products simply by Paradigm Medical Communications, LLC.

Terms associated with Use plus Privacy Policy
Please note
The materials provided designed for this activity are just for informational purposes only and should not be used for diagnosis or treatment of the health problem without consulting a licensed medical professional. This CME exercise represents the views and opinions of the individual faculty, and does not constitute the particular opinion or endorsement of, or advertising by, Paradigm Medical Communications, LLC. References to any entity, product, service, or even source of details on this website should not really be considered an recommendation, either direct or implied, by Paradigm Medical Marketing communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this action.

Privacy policy
Paradigm Medical Marketing communications, LLC or hosted contracted partner is definitely committed in order to protecting the particular privacy associated with those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for the purpose of safeguarding individual information and the rationale for collection plus use of personal information.

Security/safeguarding private information
This website has physical and procedural safeguards in place to prevent unauthorized access to private information used to access this website.

Collection and use associated with your personal information
The submission of certain personally identifiable information is necessary in order to award plus track the particular credits individuals may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to total an evaluation of the CME activity. Almost all evaluative info submitted is collected and retained, plus used by Paradigm Healthcare Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or even share personal data with outside parties. Paradigm Medical Marketing communications, LLC will not otherwise divulge personal details unless required to in a legal process. Paradigm Medical Communications, LLC staff members review person test results to the extent necessary to record and track participants’ credits.


Contact Us

If you have any kind of questions or comments, please email us at [email protected] com .

© 2022 Paradigm Healthcare Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written authorization of Paradigm Medical Communications, LLC.

Leave a Reply

Your email address will not be published. Required fields are marked *